Patient Portal

Andrea Wang-Gillam, MD, PhD

Associate Professor, Medicine
Division of Oncology
Section of Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Gastrointestinal Oncology
Pancreatic Cancer

Board Certifications

Medical Oncology
Internal Medicine

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

gastrointestinal cancer, pancreatic cancer

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Barnes-Jewish West County Hospital
Medical Building Two

10 Barnes West Drive
Creve Coeur, MO 63141

Office Phone: 314-747-1171
Fax: 314-362-3646
Email: AWang-Gillam@WUSTL.EDU

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171
Additional Phone: 314-362-5740
Fax: 314-362-7086
Email: AWang-Gillam@WUSTL.EDU

Education

Education

Fellowship: Hematology-Oncology, University of Arkansas for Medical Science, Little Rock, Arkansas 2007
Residency: Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas 2004
Ph.D.: School of Medicine, University of Arkansas for Medical Science, Little Rock, Arkansas 2001
Medical Degree: School of Medicine, University of Arkansas for Medical Science, Little Rock, Arkansas 2001

Publication & Research

Publication & Research

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM
Cancer Med. 2019 Jul 26; doi: 10.1002/cam4.2425.

PMID:
    31347292
    [PubMed - as supplied by publisher]
Related citations


Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.
Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC
J Gastrointest Oncol. 2019 Jun; 10(3)412-420. doi: 10.21037/jgo.2019.02.01.

PMID:
    31183190
    [PubMed]
Related citations


Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM
Clin Cancer Res. 2019 May 24; doi: 10.1158/1078-0432.CCR-18-2992.

PMID:
    31126960
    [PubMed - as supplied by publisher]
Related citations


Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis.
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG
J Natl Cancer Inst. 2019 May 14; pii: djz073. doi: 10.1093/jnci/djz073.

PMID:
    31086963
    [PubMed - as supplied by publisher]
Related citations


PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL
Radiology. 2019 Apr; 291(1)271. doi: 10.1148/radiol.2019194006.

PMID:
    30897045
    [PubMed]
Related citations


Targeting Stroma: A Tale of Caution.
Wang-Gillam A
J Clin Oncol. 2019 May 1; 37(13)1041-1043. doi: 10.1200/JCO.19.00056.

PMID:
    30860950
    [PubMed - in process]
Related citations


Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA
J Geriatr Oncol. 2019 May; 10(3)427-435. doi: 10.1016/j.jgo.2019.02.011.

PMID:
    30842038
    [PubMed - in process]
Related citations


NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT
Eur J Cancer. 2019 Feb; 10878-87. doi: 10.1016/j.ejca.2018.12.007.

PMID:
    30654298
    [PubMed - in process]
Related citations


Pancreas Cancer-Associated Weight Loss.
Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L, Precision Promise Consortium.
Oncologist. 2019 May; 24(5)691-701. doi: 10.1634/theoncologist.2018-0266.

PMID:
    30591550
    [PubMed - in process]
Related citations


Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT
Eur J Cancer. 2019 Jan; 10624-33. doi: 10.1016/j.ejca.2018.09.029.

PMID:
    30458340
    [PubMed - in process]
Related citations


Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA
Eur J Cancer. 2018 Dec; 10571-78. doi: 10.1016/j.ejca.2018.09.010.

PMID:
    30414528
    [PubMed - in process]
Related citations


Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.
Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH
Mol Cancer Ther. 2018 Oct; 17(10)2144-2155. doi: 10.1158/1535-7163.MCT-17-1142.

PMID:
    30065098
    [PubMed - in process]
Related citations


Dynamic changes during the treatment of pancreatic cancer.
Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ
Oncotarget. 2018 Mar 13; 9(19)14764-14790. doi: 10.18632/oncotarget.24483.

PMID:
    29599906
    [PubMed]
Related citations


Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer.
Lang GD, Mullady DK, Early DS, Hollander T, Edmundowicz SA, Murad FM, Strasberg SM, Fields RC, Hawkins WG, Doyle MB, Chapman WC, Wang-Gillam A, Kushnir VM
Clin Gastroenterol Hepatol. 2018 Nov; 16(11)1834-1835. doi: 10.1016/j.cgh.2018.02.031.

PMID:
    29505906
    [PubMed - in process]
Related citations


Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.
Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH
Cancer Res. 2018 Apr 1; 78(7)1700-1712. doi: 10.1158/0008-5472.CAN-17-1366.

PMID:
    29363544
    [PubMed - indexed for MEDLINE]
Related citations


Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer.
Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC
J Gastrointest Oncol. 2017 Dec; 8(6)985-989. doi: 10.21037/jgo.2017.08.16.

PMID:
    29299358
    [PubMed]
Related citations


First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT
Cancer Discov. 2018 Feb; 8(2)184-195. doi: 10.1158/2159-8290.CD-17-1119.

PMID:
    29247021
    [PubMed - indexed for MEDLINE]
Related citations


HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE
J Clin Oncol. 2018 Feb 1; 36(4)359-366. doi: 10.1200/JCO.2017.74.9564.

PMID:
    29232172
    [PubMed - indexed for MEDLINE]
Related citations


Trends in Neoadjuvant Approaches in Pancreatic Cancer.
Du L, Wang-Gillam A
J Natl Compr Canc Netw. 2017 Aug; 15(8)1070-1077. doi: 10.6004/jnccn.2017.0134.

PMID:
    28784867
    [PubMed - indexed for MEDLINE]
Related citations


Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma.
So E, Crees ZD, Crites D, Wang-Gillam A
J Pancreat Cancer. 2017; 3(1)49-52. doi: 10.1089/pancan.2017.0012.

PMID:
    30631842
    [PubMed]
Related citations